Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gleevec in Recurrent Platinum-Resistant, Taxane-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT00510653Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2002
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2002; status: completed.
02
Drugs
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00510653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00510653.